Skip to main
MLYS
MLYS logo

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics is positioned favorably due to the promising results of lorundrostat, which has demonstrated a significant placebo-adjusted blood pressure benefit exceeding 10mmHg in patients with uncontrolled and resistant hypertension. The drug's differentiated profile has garnered attention from key opinion leaders (KOLs) and stands in contrast to Phase 3 competitor data, suggesting a competitive advantage in the market. Furthermore, near-term FDA feedback and an anticipated New Drug Application (NDA) submission add to the positive outlook for the company's future financial performance and market potential.

Bears say

Mineralys Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential failure of its product candidate, lorundrostat, to achieve anticipated commercial revenue. Concerns include the difficulty of accessing adequate capital resources necessary for operational funding, which is critical for ongoing program development and commercialization efforts. Additionally, there are uncertainties related to market size and pricing strategies, which could adversely affect the overall market penetration of their treatment for uncontrolled hypertension.

MLYS has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 5 analysts, MLYS has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.